Comparison of current evidence from randomized clinical trials and observational studies for immunogenicity in variable meningococcal C vaccine schedules in children, adolescents, and adults


Journal Title

Journal ISSN

Volume Title



Even as early as age 10, older age correlated with increased duration of protection. Seroprotective antibody titers in infants were short-lived after primary schedule vaccinations were completed, and by 12 months of age, only 40-69% of subjects retained defined titers adequate for short term protective immunity. Combined vaccinations with routine childhood immunizations were well tolerated. Available evidence suggests that 2 or fewer doses during infancy is highly effective and immunogenic, even beginning as early as 2 months of age. In nearly all schedules, tetanus toxid (TT) carrier vaccines were more immunogenic than their diphtheria toxin mutant 197 (CRM or CRM197) protein carrier equivalents. This was less pronounced with 3 doses in infancy, and by 12 months of age antibody titers waned similarly regardless of the vaccine used. Single or booster doses given at 1-10 years of age maintain protective serum titers for 3 years in approximately 60% of children. A single or booster dose given after 11 years of age is expected to provide immunity for approximately 75% of children over 5-7 years.



meningococcal, vaccine, vaccine schedule, meningitis, conjugate vaccine